Nanobiotix (NASDAQ:NBTX) Stock Price Up 5.8% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price rose 5.8% on Friday . The company traded as high as $21.12 and last traded at $21.23. Approximately 212 shares changed hands during trading, a decline of 99% from the average daily volume of 38,057 shares. The stock had previously closed at $20.06.

Wall Street Analyst Weigh In

NBTX has been the topic of several research analyst reports. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday. Finally, Wall Street Zen raised Nanobiotix to a “hold” rating in a report on Saturday, October 25th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $11.00.

Nanobiotix Stock Performance

The company has a 50 day simple moving average of $21.56 and a two-hundred day simple moving average of $16.26.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.